STAAR Surgical posts preliminary merger vote results

Rhea-AI Filing Summary

STAAR Surgical Company reported that it held a special meeting of stockholders on January 6, 2026 to consider proposals related to its Agreement and Plan of Merger with Alcon Research, LLC and Rascasse Merger Sub, Inc. The merger agreement was originally dated August 4, 2025 and had been amended on November 7, 2025 and December 9, 2025. The company stated that it issued a press release announcing the preliminary voting results from this special meeting, which is included as Exhibit 99.1 to the report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did STAAR Surgical (STAA) announce in this Form 8-K?

STAAR Surgical reported that it held a special meeting of stockholders on January 6, 2026 to consider proposals related to its merger agreement with Alcon Research, LLC and Rascasse Merger Sub, Inc., and that it issued a press release with preliminary voting results.

What merger is STAAR Surgical (STAA) stockholders considering?

Stockholders are considering proposals related to an Agreement and Plan of Merger among STAAR Surgical Company, Alcon Research, LLC, and Rascasse Merger Sub, Inc., originally dated August 4, 2025 and subsequently amended on November 7, 2025 and December 9, 2025.

When was the STAAR Surgical special meeting on the Alcon merger held?

The special meeting of STAAR Surgical stockholders to consider proposals related to the merger agreement with Alcon was held on January 6, 2026.

Does the filing include the preliminary voting results for STAAR Surgical (STAA)?

The filing states that STAAR Surgical issued a press release announcing the preliminary voting results of the special meeting, and that this press release is attached as Exhibit 99.1.

How many times has the STAAR–Alcon merger agreement been amended?

The merger agreement among STAAR Surgical, Alcon Research, LLC, and Rascasse Merger Sub, Inc. has been amended twice, by Amendment No. 1 on November 7, 2025 and Amendment No. 2 on December 9, 2025.

Where can investors find more details on STAAR Surgical’s preliminary merger vote?

More detail on the preliminary voting results is provided in the press release referenced in the report and attached as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 09:01 AM EST Learn about SEC filing dates

STAAR SURGICAL CO false 0000718937 0000718937 2026-01-06 2026-01-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 6, 2026

STAAR Surgical Company

(Exact name of registrant as specified in its charter)

Delaware		0-11634		95-3797439
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)
25510 Commercentre Drive Lake Forest, California				92630
(Address of principal executive offices)				(Zip Code)

626-303-7902

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common		STAA		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 6, 2026, STAAR Surgical Company, a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Agreement and Plan of Merger, dated as of August 4, 2025, by and among Alcon Research, LLC, a Delaware limited liability company (“Alcon”), Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Alcon (“Merger Sub”), and the Company (as it may be amended from time to time, including by Amendment No. 1 on November 7, 2025 and Amendment No. 2 on December 9, 2025, the “Merger Agreement”). The Company issued a press release announcing the preliminary voting results of the Special Meeting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibit
99.1		Press Release, dated as of January 6, 2026
104		Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				STAAR Surgical Company
Date: January 6, 2026				By:		/s/ Stephen C. Farrell
				Name:		Stephen C. Farrell
				Title:		Chief Executive Officer